ArticleBMC medical imaging2025
CT habitat radiomics and topological data analysis based on interpretable machine learning for prediction of pancreatic ductal adenocarcinoma pathological grading.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heterogeneity Analyzed by CT-Based Habitat Analysis for Clinical Management of Cancers: A Narrative Review.The Kaohsiung journal of medical sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study explores the feasibility and effectiveness of an interpretable machine learning model for assessing the pathological grading of pancreatic ductal adenocarcinoma (PDAC) using radiomics and topological features derived from contrast-enhanced CT habitat subregions.
methodsA retrospective study was conducted on a total of 306 patients with PDAC from two hospitals: a training cohort (n = 176), a validation cohort (n = 76), and a test cohort (n = 54). K-means clustering analysis was first used to segment portal venous phase CT images into three habitat regions. Radiomics features of the whole-tumour region, along with radiomics and topological features of each habitat region, were extracted respectively. LASSO regression was applied for feature dimensionality reduction to construct the radiomics score (Rad-score) for the whole-tumour region and the habitat score (H-score) for each habitat region. Meanwhile, logistic regression was used to identify statistically significant predictors from clinical and semantic features. Five machine learning algorithms were used to construct Habitat-TDA models, with interpretability analysis performed via SHAP analysis.
resultsTotal volume, diabetes, and M staging were identified as independent risk factors for predicting the pathological grading of PDAC, and were used to construct the Clinical model. 6 radiomics features with non-zero coefficients were selected to calculate the Rad-score, which was further used to construct the WholeRad model. In the three habitat regions, 6, 5, and 6 topological and radiomics features were included to generate the H-score. The logistic regression algorithm performed best in the validation and test cohorts and was ultimately selected as the classifier for constructing the Habitat-TDA model. SHAP analysis showed that H-score1, derived from Habitat Region 1 (the habitat region with the lowest average CT value), has the most significant average impact on the model output intensity. The AUC values of the Habitat-TDA model in the training, validation, and test cohorts were 0.894, 0.872, and 0.829, all outperforming the clinical model (0.784, 0.765, 0.731) and WholeRad model (0.817, 0.810, 0.773).
conclusionsThe Habitat-TDA model improves the accuracy and interpretability of preoperative predictions of PDAC grading, providing a promising tool for personalised management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.